CY1123337T1 - Ειδικα σχεδιασμενα λιποσωματα για τη θεραπεια βακτηριακων μολυνσεων - Google Patents
Ειδικα σχεδιασμενα λιποσωματα για τη θεραπεια βακτηριακων μολυνσεωνInfo
- Publication number
- CY1123337T1 CY1123337T1 CY20201100878T CY201100878T CY1123337T1 CY 1123337 T1 CY1123337 T1 CY 1123337T1 CY 20201100878 T CY20201100878 T CY 20201100878T CY 201100878 T CY201100878 T CY 201100878T CY 1123337 T1 CY1123337 T1 CY 1123337T1
- Authority
- CY
- Cyprus
- Prior art keywords
- liposomes
- treatment
- liposomes containing
- sphingomyelin
- lipid composition
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title abstract 9
- 208000035143 Bacterial infection Diseases 0.000 title abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
- 150000002632 lipids Chemical class 0.000 abstract 3
- 235000012000 cholesterol Nutrition 0.000 abstract 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 2
- 239000003053 toxin Substances 0.000 abstract 2
- 231100000765 toxin Toxicity 0.000 abstract 2
- 108700012359 toxins Proteins 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 231100000699 Bacterial toxin Toxicity 0.000 abstract 1
- 239000000232 Lipid Bilayer Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 206010035734 Pneumonia staphylococcal Diseases 0.000 abstract 1
- 241000191967 Staphylococcus aureus Species 0.000 abstract 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 abstract 1
- 241000193998 Streptococcus pneumoniae Species 0.000 abstract 1
- 239000000688 bacterial toxin Substances 0.000 abstract 1
- 230000009089 cytolysis Effects 0.000 abstract 1
- 230000034994 death Effects 0.000 abstract 1
- 231100000636 lethal dose Toxicity 0.000 abstract 1
- 239000013554 lipid monolayer Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000004048 staphylococcal pneumonia Diseases 0.000 abstract 1
- 208000011437 staphylococcus aureus pneumonia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12171924 | 2012-06-14 | ||
| EP13153039 | 2013-01-29 | ||
| PCT/EP2013/062207 WO2013186286A1 (en) | 2012-06-14 | 2013-06-13 | Tailored liposomes for the treatment of bacterial infections |
| EP13732388.7A EP2861214B1 (en) | 2012-06-14 | 2013-06-13 | Tailored liposomes for the treatment of bacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123337T1 true CY1123337T1 (el) | 2021-12-31 |
Family
ID=48703423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100878T CY1123337T1 (el) | 2012-06-14 | 2020-09-16 | Ειδικα σχεδιασμενα λιποσωματα για τη θεραπεια βακτηριακων μολυνσεων |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US10744089B2 (enExample) |
| EP (2) | EP3782606A1 (enExample) |
| JP (2) | JP6382801B2 (enExample) |
| CN (2) | CN109549925B (enExample) |
| AU (2) | AU2013276565B2 (enExample) |
| BR (1) | BR112014031278B1 (enExample) |
| CA (1) | CA2875470C (enExample) |
| CY (1) | CY1123337T1 (enExample) |
| DK (1) | DK2861214T3 (enExample) |
| ES (1) | ES2821502T3 (enExample) |
| HR (1) | HRP20201761T1 (enExample) |
| HU (1) | HUE051761T2 (enExample) |
| LT (1) | LT2861214T (enExample) |
| PL (1) | PL2861214T3 (enExample) |
| RS (1) | RS60951B1 (enExample) |
| RU (1) | RU2672106C2 (enExample) |
| SI (1) | SI2861214T1 (enExample) |
| SM (1) | SMT202000584T1 (enExample) |
| WO (1) | WO2013186286A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2875470C (en) * | 2012-06-14 | 2021-01-12 | Universitaet Bern | Tailored liposomes for the treatment of bacterial infections |
| WO2015084677A1 (en) | 2013-12-02 | 2015-06-11 | Arytha Biosciences, Llc | Toxoid preparation and uses thereof |
| US10739353B2 (en) * | 2014-12-31 | 2020-08-11 | Signpath Pharma, Inc. | Suppression of cytokine release and cytokine storm |
| WO2017115358A1 (en) | 2015-12-28 | 2017-07-06 | Mb Biotech Ltd. | Liposomes for treatment of an autoimmune disease |
| WO2017177073A1 (en) * | 2016-04-07 | 2017-10-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Francisella lipids as broad anti-inflammatory therapeutics and associated methods of use |
| PL3471732T3 (pl) | 2016-06-16 | 2020-10-19 | Combioxin Sa | Liposomy do leczenia infekcji wirusowych |
| WO2018158375A1 (en) | 2017-03-02 | 2018-09-07 | Combioxin Sa | Liposomes for inhibiting biofilm formation |
| US11344497B1 (en) | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
| LT3781172T (lt) * | 2018-04-17 | 2023-11-10 | Combioxin Sa | Pneumonijos gydymas |
| SMT202400412T1 (it) | 2018-04-20 | 2024-11-15 | Combioxin Sa | Trattamento dell'ipotensione con sepsi o shock settico |
| CN111214439B (zh) * | 2018-11-23 | 2023-02-10 | 复旦大学 | 一种具有细菌成孔毒素吸附性能的纳米药物系统及其用途 |
| JP2023536833A (ja) * | 2020-07-31 | 2023-08-30 | サインパス ファルマ，インク． | サイトカイン放出及びサイトカインストームの抑制 |
| CN115054577B (zh) * | 2022-05-17 | 2024-06-21 | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | 纳米解毒剂及其在中和mrsa穿孔毒素的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991004019A1 (en) * | 1989-09-12 | 1991-04-04 | The Regents Of The University Of California | Therapeutic peptides and proteins |
| NL9000207A (enExample) * | 1990-01-29 | 1991-08-16 | Duphar Int Res | |
| WO1993004672A1 (en) | 1991-09-11 | 1993-03-18 | Pitman-Moore, Inc. | Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides |
| US5741516A (en) * | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5543152A (en) * | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US6726925B1 (en) * | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
| US8110217B2 (en) * | 2001-08-13 | 2012-02-07 | University Of Pittsburgh | Sphingomyelin liposomes for the treatment of hyperactive bladder disorders |
| EP1443900B1 (en) * | 2001-11-13 | 2012-05-23 | Celator Pharmaceuticals, Inc. | Lipid carrier compositions with enhanced blood stability |
| CA2368656A1 (en) * | 2002-01-21 | 2003-07-21 | Vasogen Ireland Limited | Receptor-ligand pairing for anti-inflammatory response |
| EP1531828A4 (en) * | 2002-05-23 | 2005-11-02 | Activbiotics Inc | METHODS OF TREATING BACTERIAL INFECTIONS AND ASSOCIATED DISEASES |
| US20040156888A1 (en) * | 2002-11-26 | 2004-08-12 | Jensen Gerard M. | Liposomal formulations |
| EP1610763A2 (en) * | 2003-03-31 | 2006-01-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Stable liposomes or micelles comprising a sphingolipid and a peg-lipopolymer |
| AU2005304914B2 (en) * | 2004-11-05 | 2012-02-16 | Tekmira Pharmaceuticals Corporation | Compositions and methods for stabilizing liposomal camptothecin formulations |
| CN1939340A (zh) * | 2005-09-29 | 2007-04-04 | 中国人民解放军军事医学科学院毒物药物研究所 | 脂质体制剂 |
| WO2008039989A2 (en) * | 2006-09-28 | 2008-04-03 | Transave, Inc. | Formulations of dnase and methods of use thereof |
| EP2088865B1 (en) * | 2006-11-06 | 2015-10-21 | Jina Pharmaceuticals Inc. | Guggulphospholipid methods and compositions |
| CN1994279A (zh) * | 2006-12-31 | 2007-07-11 | 西安力邦医药科技有限责任公司 | 注射用盐酸伊立替康脂质体的制备方法 |
| CN101623262B (zh) * | 2009-08-24 | 2011-02-02 | 海南美大制药有限公司 | 一种五水头孢唑啉钠前体脂质体制剂 |
| CN107261110A (zh) * | 2010-06-19 | 2017-10-20 | 健康科学西部大学 | Peg化脂质体包封的糖肽抗生素的新制剂 |
| SG187770A1 (en) * | 2010-08-12 | 2013-03-28 | Univ Nanyang Tech | A liposomal formulation for ocular drug delivery |
| CN102327220B (zh) | 2011-07-14 | 2012-09-26 | 海南灵康制药有限公司 | 一种氯雷他定脂质体固体制剂 |
| CA2875470C (en) * | 2012-06-14 | 2021-01-12 | Universitaet Bern | Tailored liposomes for the treatment of bacterial infections |
-
2013
- 2013-06-13 CA CA2875470A patent/CA2875470C/en active Active
- 2013-06-13 WO PCT/EP2013/062207 patent/WO2013186286A1/en not_active Ceased
- 2013-06-13 HU HUE13732388A patent/HUE051761T2/hu unknown
- 2013-06-13 HR HRP20201761TT patent/HRP20201761T1/hr unknown
- 2013-06-13 US US14/404,985 patent/US10744089B2/en active Active
- 2013-06-13 SM SM20200584T patent/SMT202000584T1/it unknown
- 2013-06-13 BR BR112014031278-8A patent/BR112014031278B1/pt active IP Right Grant
- 2013-06-13 SI SI201331806T patent/SI2861214T1/sl unknown
- 2013-06-13 AU AU2013276565A patent/AU2013276565B2/en active Active
- 2013-06-13 RS RS20201252A patent/RS60951B1/sr unknown
- 2013-06-13 DK DK13732388.7T patent/DK2861214T3/da active
- 2013-06-13 CN CN201811433069.8A patent/CN109549925B/zh active Active
- 2013-06-13 LT LTEP13732388.7T patent/LT2861214T/lt unknown
- 2013-06-13 EP EP20189368.2A patent/EP3782606A1/en active Pending
- 2013-06-13 ES ES13732388T patent/ES2821502T3/es active Active
- 2013-06-13 PL PL13732388T patent/PL2861214T3/pl unknown
- 2013-06-13 CN CN201380031384.7A patent/CN104602672B/zh active Active
- 2013-06-13 EP EP13732388.7A patent/EP2861214B1/en active Active
- 2013-06-13 RU RU2014148284A patent/RU2672106C2/ru active
- 2013-06-13 JP JP2015516609A patent/JP6382801B2/ja active Active
-
2018
- 2018-08-02 JP JP2018145681A patent/JP6656321B2/ja active Active
-
2019
- 2019-03-14 AU AU2019201776A patent/AU2019201776B2/en active Active
-
2020
- 2020-07-09 US US16/924,539 patent/US20200345639A1/en not_active Abandoned
- 2020-09-16 CY CY20201100878T patent/CY1123337T1/el unknown
-
2021
- 2021-11-30 US US17/537,862 patent/US20220087934A1/en not_active Abandoned
-
2022
- 2022-09-30 US US17/957,402 patent/US20230031648A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123337T1 (el) | Ειδικα σχεδιασμενα λιποσωματα για τη θεραπεια βακτηριακων μολυνσεων | |
| AR123996A2 (es) | Compuestos tricíclicos novedosos como agentes antineoplásicos | |
| BR112014004704A2 (pt) | compostos antibacterianos e métodos de uso | |
| BR112014022214A2 (pt) | fenólicos antibacterianos | |
| CY1121701T1 (el) | Οργανικες ενωσεις μονοβακταμης για την αντιμετωπιση βακτηριακων λοιμωξεων | |
| BR112013026308A2 (pt) | Compostos de benzeno substituídos | |
| BR112014004832A2 (pt) | compostos antibacterianos e métodos para uso | |
| IL240283A (en) | Topical veterinary compositions comprising an isoxazoline active agent, methods and uses thereof for treating or preventing a parasitic infection or infestation in a mammal | |
| BR112015027704A2 (pt) | Composto, uso do mesmo e composição farmacêutica antibacteriana | |
| BR112015016001A2 (pt) | compostos, composições farmacêuticas e respectivos usos e método para tratar ou prevenir infecção bacteriana | |
| BR112015029367A2 (pt) | terapia combinada compreendendo oxazolidinona-quinolonas para uso no tratamento de infecções bacterianas | |
| JP2015528502A5 (enExample) | ||
| BR112013029692A2 (pt) | derivados de imidazol úteis para o tratamento da artrite | |
| BR112012005970A2 (pt) | moduladores tricíclicos de proteína quinase | |
| BR112014021498A2 (pt) | composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado | |
| HK1213264A1 (zh) | 经取代的苯化合物 | |
| BR112017010132A2 (pt) | terapia combinada para tratamento de infecções bacterianas resistentes | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| BR112012005957A2 (pt) | compostos tricíclicos e usos farmacêuticos dos mesmos | |
| RU2014149351A (ru) | Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий | |
| BR112014031866A2 (pt) | Composição farmacêutica intramamária para utilização no tratamento ou prevenção da mastite em um mamífero não humano e composição farmacêutica de fosfomicina e de pelo menos um anti-microbiano | |
| BR112016005271A2 (pt) | Moduladores de canais de sódio para o tratamento da dor e do diabetes | |
| BRPI1010948A2 (pt) | Composição compreendendo pelo menos trans- cinamaldeído e a respectiva utilização no tratamento das infecções bacterianas, mais particularmente no tratamento das doenças nosocomiais. | |
| MX2014001600A (es) | 3,4-dihidro-1h-[1,8]naftiridinosas antibacterianas sustituidas con ciclopenta[c]pirrol. | |
| CO6741223A2 (es) | Derivados de azetidina útiles para el tratamiento de enfermedades metabólicas e inflamatorias |